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Abstract
Background: There is concern about an increasing infiltration of markets by substandard and fake
medications against life-threatening diseases in developing countries. This is particularly worrying
with regard to the increasing resistance development of Plasmodium falciparum against affordable
anti-malarial medications, which has led to a change to more expensive drugs in most endemic
countries.
Methods: A representative sample of modern anti-malarial medications from licensed (public and
private pharmacies, community health workers) and illicit (market and street vendors, shops)
sources has been collected in the Nouna Health District in north-western Burkina Faso in 2006.
All drugs were tested for their quality with the standard procedures of the German Pharma Health
Fund-Minilab. Detected low standard drugs were re-tested with European Pharmacopoeia 2.9.1
standards for disintegration and ultraviolet-visible spectroscopy at the laboratory of the Heidelberg
University for confirmation.
Results: Overall, 86 anti-malarial drug samples were collected, of which 77 samples have been
included in the final analysis. The sample consisted of 39/77 (50%) chloroquine, 10/77 (13%)
pyrimethamine-sulphadoxine, 9/77 (12%) quinine, 6/77 (8%) amodiaquine, 9/77 (12%) artesunate,
and 4/77 (5%) artemether-lumefantrine. 32/77 (42%) drug samples were found to be of poor
quality, of which 28 samples failed the visual inspection, nine samples had substandard
concentrations of the active ingredient, four samples showed poor disintegration, and one sample
contained non of the stated active ingredient. The licensed and the illicit market contributed 5/47
(10.6%) and 27/30 (90.0%) samples of substandard drugs respectively.
Conclusion:  These findings provide further evidence for the wide-spread existence of
substandard anti-malarial medications in Africa and call for strengthening of the regulatory and
quality control capacity of affected countries, particularly in view of the now wider available and
substantially more costly artemisinin-based combination therapies.
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Background
Malaria remains the globally most important parasitic dis-
ease. Out of the approximately one million deaths caused
by malaria each year, the great majority occurs in children
under the age of five years living in sub-Saharan Africa
(SSA) [1].
Malaria, if treated early with effective drugs, is fully cura-
ble. However, most of the affected children live in remote
and poor communities with low access to functioning
modern health services [1,2]. As a result, children are
either not treated at all, receive traditional treatment of
uncertain efficacy, or are treated with drugs primarily
bought at the informal drug sector [1,3].
In recent years, increasing numbers of substandard and
fake medications were detected in the international mar-
kets, but precise figures of the global situation are lacking.
It is estimated that more than 10% of the globally traded
medicines are counterfeits [4,5]. In developing countries,
where regulatory and control mechanisms are weak, peo-
ple are at highest risk to purchase substandard medica-
tions [4,6,7]. Seiter concluded in 2005: "Pharmaceutical
products are attractive candidates for illegal trade, espe-
cially in developing countries. They are easily transporta-
ble, have high value per unit, and most importantly, their
quality cannot be assessed readily by lay persons or even
experts without the aid of a quality testing laboratory" [8].
Drugs to treat infectious diseases, like malaria, pneumo-
nia or diarrhoea, are frequently a target of criminal action
[5,9,10].
After the marketing of the artemisinin-based combination
therapy (ACT) against malaria in Asia, these costly drugs
were found to be counterfeit in 38% and 53% in two stud-
ies conducted in different countries of south-east Asia
[11,12]. In Cambodia, for example, it was shown that fake
artesunate was sold by 71% of local drug vendors [13].
Globally it is estimated that more than US$ 30 billion per
year are earned by the overall trade of substandard and
counterfeit drugs and this will probably increase to US$
75 billion by the year 2010 [8,14].
The intake of fake medicaments can lead to life-threaten-
ing consequences [5,7,11]. Especially for diseases carrying
a high mortality if left untreated, like malaria, substand-
ard drugs will raise death rates. Furthermore, such drugs
can lead to numerous adverse drug effects due to under-
dosing, over-dosing, and unexpected or toxic substances
[5,11]. Moreover, it will influence the economic welfare of
patients, health systems, and drug companies that pro-
duce genuine products [11]. Finally, it will most likely
increase the risk of selection and spreading of drug resist-
ance [11]. Fake drugs, furthermore, can lead to biased data
on drug resistance or drug efficacy studies [9,15].
The World Health Organization (WHO), thus, recom-
mended taking action against substandard drugs at the
individual country level [16]. This recommendation is
supported by the German Pharma Health Fund (GPHF)
that designed an affordable laboratory kid for screening
drugs even under tropical conditions. The GPHF-Minilab
is working with widely available reagents and can also be
run without electricity [17-21]. The GPHF-Minilab oper-
ates in a four step procedure, including two physical
methods (visual inspection and disintegration test) and
two chemical methods (qualitative colour reaction test
and semi-quantitative thin-layer chromatography) [20].
The aim of this study was to evaluate the presence of sub-
standard anti-malarial drugs in the public, private, and
informal markets of Burkina Faso.
Methods
Study area
The study was carried out in the Nouna Health District
(NHD), a rural, multi-ethnic area of north-western
Burkina Faso, West Africa. Most of the estimated 280,000
inhabitants of NHD are living under self-subsistence con-
ditions. Malaria is the main cause of morbidity and mor-
tality in the NHD as in the whole of Burkina Faso [22].
Formal health services in NHD comprise of 25 primary
health care facilities, which are covering the needs of a var-
iable number of villages, and the district hospital in
Nouna town [2]. NHD is holoendemic for malaria with
elevated transmission rates during and shortly after the
rainy season, which typically lasts from June to October
[22].
Study design and procedures
This cross-sectional study was carried out during the rainy
season of 2006. Drugs were sampled in August and Sep-
tember which are known to be the months of most
intense drug sale in this area of West Africa [23].
Anti-malarial drugs were collected from a sample of 16
villages (based on specific information from the results of
a representative anti-malarial drug provider study con-
ducted in early 2006 in the whole of NHD), and in Nouna
town. After identification of all points of drug sale in these
villages, anti-malarial drug samples were purchased from
markets, street vendors, shops, private pharmacies, com-
munity health workers, and the governmental pharmacies
attached to the peripheral health centres. Each market
place was defined as one point of sale and the drug collec-
tion was carried out on respective market days. For the
analysis, private pharmacies, community health workers,
and the health centre and hospital pharmacies were
defined as licensed market, while markets, street vendors,
and shops were summarized as illicit market. The sample
consisted of tablets and capsules of chloroquine, amodi-Malaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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aquine, sulphadoxine/pyrimethamine, quinine, artesu-
nate and, artemether-lumefantrine.
Drugs were purchased by one field worker who behaved
like a normal client. Each sample of a drug was labelled
with an identification number and put into a plastic bag
without any further manipulation. A drug collection
sheet, which provided information on the date, place, and
conditions of purchase, the name of the drug indicated by
the vendor and the name stated on the product, the active
ingredient and the price, was filled in immediately. After
purchase, all drug samples have been stored in a dark, dry
and air conditioned place inside the laboratory building
of the Centre de Recherche en Santé de Nouna (CRSN).
At the time-point of the study no artemisinin drugs or
ACT were available in the NHD, except in the two private
pharmacies in Nouna town. To get a broader impression
on the quality of artemisinin drugs or ACT in Burkina
Faso, a convenience sample of such products was taken
from market places and private pharmacies in randomly
selected quarters of Ougadougou, the capital of Burkina
Faso.
Laboratory work
The initial testing of all drug samples was performed at the
laboratory of the CRSN with the German Pharma Health
Fund (GPHF)-Minilab. Two physical methods (visual
inspection and disintegration test) and two chemical
methods (qualitative colour reaction test and semi-quan-
titative thin-layer chromatography) were performed
according to the existing GPHF-Minilab standards. All
data was noted down in the specific "reporting forms" of
the GPHF-Minilab.
GPHF-Minilab procedures were performed by the two
investigators (MT and SD). In case a sample failed the vis-
ual inspection by one of the investigators it was re-exam-
ined by the second investigator for confirmation.
Furthermore, in cases of doubt external aid was consulted
(e.g. internet research on manufactures information and
figures provided on homepages). Drug samples which
failed the colour reaction by the first investigator, i.e. none
of the stated and expected active ingredient was present,
were retested in a second run by the respectively second
investigator for confirmation. The aim of this procedure
was to confirm the coherence of the stated and actually
present active ingredient. Further investigations to deter-
mine potential other present active ingredients, which
were not indicated, were therefore, not performed.
Drug samples that failed the disintegration test or semi-
quantitative thin-layer chromatography in the GPHF-
Minilab testings, were sent to Germany, where confirma-
tory tests took place at the laboratory of the pharmacy of
the Heidelberg University. The confirmatory disintegra-
tion tests were performed according to European Pharma-
copoeia 2.9.1 [24]. The quantification of the active
ingredient of respective samples was done with the ultra-
violet-visible spectroscopy [25,26]. The German investiga-
tors were blinded to the origin of respective samples.
Data analysis
All data were transferred into a Microsoft Excel database.
The descriptive analysis was done by SPSS 12.0 for Win-
dows.
Ethical aspects
The study is part of the A8 study of the SFB 544, which has
been approved by the local Ethical Committee of the
CRSN, Burkina Faso, and by the Ethical Committee of the
Heidelberg University. The specific study procedures were
discussed and approved by the responsible authorities of
the NHD. At each point of sale, not more than 50% of the
total amount of available malaria drugs was purchased.
Results
A total of 86 anti-malarial drug samples have been col-
lected, 79 came from the NHD and seven from Ouaga-
dougou (Figure 1). Of these, 48/86 (56%) were
chloroquine samples, 6/86 (7%) were amodiaquine sam-
ples, 10/86 (12%) were pyrimethamine-sulphadoxine
samples, 9/86 (10%) were quinine samples, and 13/86
(15%) were artemisinin or ACT samples (of those, six
were from NHD and seven from Ouagadougou).
Overall, 18/86 (21%) samples, which had failed the
GPHF-Minilab disintegration and/or semi-quantitative
thin-layer chromatography tests, were re-tested for confir-
mation. Another 9/86 (10%) drug samples showed tailing
phenomena in the GPHF-Minilab semi-quantitative thin-
layer chromatography. Tailing phenomena indicate possi-
ble auxiliary substances in the respective drug samples (all
nine samples were chloroquine). These samples were also
referred for further investigation to the pharmacy of the
University of Heidelberg. Here it was concluded that these
phenomena were most probably caused by povidone,
which are widely used as excipient in tablets. As it cannot
be excluded that other unknown substances have caused
the tailing phenomena, these nine samples were excluded.
Thus, 77 anti-malarial drug samples were finally included
in the analysis (Figure 1, Table 1). Of these, 47/77 (61%)
were from the licensed market and 30/77 (39%) were
from the illicit market (Table 2).
In total, 32/77 (41.6%) anti-malarial drug samples were
found to be of substandard quality, of which 28/32 (88%)
samples failed the visual inspection. These samples have
been chloroquine, 23/28 (82%); sulphadoxine/pyrimeth-
amine, 4/28 (14%); and artesunate, 1/28 (4%). 4/32Malaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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(13%) samples were found to be of poor disintegration
(three chloroquine, one sulphadoxine/pyrimethamine)
(Table 3).
One of 32 (3%) samples (sulphadoxine/pyrimethamine)
failed the colour reaction, indicating neither sulphadox-
ine nor pyrimethamine was present in this sample. This
sample, thus, was excluded from the following semi-
quantitative thin-layer chromatography tests and ultravio-
let-visible spectroscopy. Here, 9/31 (29%) anti-malarial
drug samples with substandard concentrations of the
respective active ingredient were detected. Of these, 5/9
(55.6%) were chloroquine, 3/9 (33.3%) were quinine,
and 1/9 (11.1%) were sulphadoxine/pyrimethamine
(Table 4).
Flow chart of study sample Figure 1
Flow chart of study sample.
GPHF = German Pharma Health Fund, TLC = Thin Layer Chromatography 
Anti-malarial drug samples 
tested with the  
GPHF-Minilab  
N=86 
Samples contained  
unidentified 
auxiliary substances 
N=9 
Samples included in the final 
analysis 
N=77 
   Samples passed  
GPHF-Minilab  
Testing 
N=45 
Samples referred for 
identification testing 
N=9 
Samples excluded 
from final analysis 
N=9 
   Samples failed  
GPHF-Minilab  
testing 
N=41 
Samples failed 
GPHF-Minilab  
testing 
N=32 
 
 18/ 32 samples reference tested at 
the University of Heidelberg 
Table 1: Origin of anti-malarial drugs included into the final analysis
NHD except Nouna town Nouna town Ouagadougou total %
Chloroquine 31 8 0 39/77 50.6
Artesunate 04 5 9 / 7 7 1 1 . 7
Lumefantrine/Artemether 02 2 4 / 7 7 5 . 2
Sulphadoxine/Pyrimethamine 7 2 0 10/77 13.0
Quinine 62 0 9 / 7 7 1 1 . 7
Amodiaquine 33 0 6 / 7 7 7 . 8
Total 47 23 7 77/77 100
NHD = Nouna Health DistrictMalaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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Substandard drugs in the licensed and illicit anti-malarial 
drug markets
Overall, 47/77 (61.0%) anti-malarial drug samples were
purchased at the licensed market and 30/77 (39.0%) at
the illicit market. 5/47 (10.6%) anti-malarial drug sam-
ples from licensed and 27/30 (90.0%) samples from illicit
sources respectively were found to be of substandard qual-
ity. Due to signs of decline of tablets, one artesunate sam-
ple in our study was found to be substandard. The
artesunate sample was labelled with the letters "not for
sale" and purchased at a market place in Ougadougou.
The visual inspection was failed by 27/30 (90.0%) anti-
malarial drug samples from the illicit market, while one
sample purchased in the licensed market did not pass.
Table 5 provides detailed information on the reasons for
not passing the visual inspection differentiated by the two
different market types. All products that failed the disinte-
gration (4/77, 5.2%) or colour reaction (1/77, 1.3%) were
purchased in the illicit market. Substandard concentra-
tions of the active ingredient were detected in 5/29
(17.2%) and 4/47 (8.5%) of anti-malarial samples from
the illicit and licensed markets respectively.
Discussion
In Burkina Faso, ACT is recommended for the treatment
of uncomplicated malaria since 2005, but until recently,
these drugs were not available through governmental
health services [2]. Also private pharmacies in this country
reported difficulties in the constant supply with ACT, due
to shortages at the wholesalers. Increasing demand,
accompanied by unavailability through legal sources, will
be likely to contribute to the growing problem of fake
medications [11]. Beside this, criminal greed, the lack of
legislation, lack of law enforcement, corruption, and com-
plex trade arrangements, are facilitating the influx of sub-
standard and counterfeit products in the developing
world [11].
The main result from this study is the large proportion of
anti-malarial drugs found to be substandard in Burkina
Faso. Nearly half of the sample showed varying degrees of
impaired quality and, probably not surprising, the great
majority of those were from the illicit market. However,
all failures detected in nevertheless which step of the qual-
ity testing procedure were treated alike in our analysis.
This is despite the fact that the different types of reduced
quality may well have different impacts (e.g. a not cor-
rectly labelled and/or sticky, broken and dirty tablet might
have contained the proper amount of active ingredient,
and thus would not have necessarily reduced treatment
success). Nevertheless, international drug quality stand-
ards should be applied worldwide.
Our results support the findings from other studies which
have addressed the topic of substandard drugs in SSA
Table 2: Points of sale and numbers of anti-malarial drugs included in the sample
NHD except Nouna town Nouna town Ouagadougou In total %
Public health facility 18 4 0 22/77 28.6
Community health worker 30 0 3 / 7 7 3 . 9
Private pharmacy 4 13 5 22/77 28.6
Shop 13 0 4 / 7 7 5 . 2
Street vendor 01 0 1 / 7 7 1 . 3
Market place 21 2 2 25/77 32.5
Total 47 23 7 77/77 100
NHD = Nouna Health District
Table 3: Number (%) of failed samples listed by the active ingredient and test
Visual inspection Disintegration test Colour reaction Thin-layer chromatography 
and ultraviolet-visible 
spectroscopy
Total
Chloroquine 23/39 (59.0%) 3/39 (7.7%) 0/39 5/39 (12.8%) 24/39* (61.5%)
Artesunate 1/9 (11.1%) 0/9 0/9 0/9 1/9 (11.1%)
Lumefantrine/
Artemether
0/4 0/4 0/4 0/4 0/4
Sulphadoxine/
Pyrimethamine
4/10 (40.0%) 1/10 (10.0%) 1/10 (10.0%) 1/10 (10.0%) 4/10* (40%)
Quinine 0/9 0/9 0/9 3/9 (33.3%) 3/9 (33.3%)
Amodiaquine 0/6 0/6 0/6 0/6 0/6
Total 28/77 (36.4%) 4/77 (5.2%) 1/77 (1.3%) 9/76 (11.8%) 32/77 (41.6%)
* Some samples failed more than one testMalaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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[9,26-35]. In a study from Cameroon for example, 32% of
chloroquine, 10% of quinine, and 13% of sulphadoxine/
phyrimethamine samples were found to be substandard
[9]. In a study on private pharmacies in Nigeria, 48% of
anti-infective drugs, including anti-malarial drugs, were
found to be of impaired quality [32].
In the illicit market, drugs are sold as blister packs, as sin-
gle tablets cut off from a blister, or just taken from big con-
tainers or plastic bags without any labelling, packaging or
instruction leaflets (Figure 2). A large proportion of anti-
malarial drugs obtained in the illicit market failed the vis-
ual inspection due to signs of decline and destruction.
This is partly explained by tablets being carried around in
huge bags from one market to the other. The substandard
physical composition of products from illegal drug
sources was also confirmed by the results of the disinte-
gration test, which is most likely related to poor storage
conditions. High temperatures and humidity can influ-
ence the dissolution rate, thus leading to suboptimal
activity of the drug due to reduced bio-availability
[30,32,36,37]. Another reason that can prevent proper
disintegration is related to the formulation of the drug
itself [36]. Deliberately counterfeit drugs might contain
substances such as flour, baking powder or other sub-
Table 4: Real value analysis of samples with substandard concentrations of the active ingredient
Active ingredient Place of purchase Real value analysis (mg) Difference
Chloroquine Phosphate (100 mg) Private pharmacy min: 89,94 10%
max: 94,08 6%
mid: 91,57 8%
Chloroquine Phosphate (100 mg) marked place min: 87,32 13%
max: 91,07 9%
mid: 88,68 11%
Chloroquine Phosphate (250 mg) marked place min: 180.16 28%
max: 221.31 11%
mid: 200.93 20%
Chloroquine Phosphate (250 mg) marked place min: 188,01 25%
max: 198,67 20%
mid: 193.34 23%
Chloroquine Phosphate (250 mg) marked place min: 188,38 25%
max: 193,79 22%
mid: 191.08 24%
Sulfadoxine/Pyrimethamine (500/25 mg) marked place only TLC > 20%
performed > 20%
Quinine Sulfate (300 mg) public health facility min: 267,42 11%
max: 291,95 3%
mid: 277.37 7%
Quinine Sulfate (300 mg) public health facility min: 176,11 41%
max: 286,60 4%
mid: 237.04 21%
Quinine Sulfate (300 mg) Privat pharmacy min: 251,11 16%
max: 276,09 8%
mid: 266.14 11%
TLC = Thin Layer Chromatography, min. = minimal detected content, max. = maximal detected content, mid. = average detected content
Table 5: Reasons for not passing the visual inspection separated by different kind of markets
Licensed market Illicit market Total
Manufacture not identified 01 4 1 4
Signs of decline* 05 5
Manufacture not identified + missing tablets 01 1
Manufacture not identified + signs of decline* 05 5
missing tablets in blister + signs of decline* 10 1
Manufacture not identified + expired + signs of decline* 01 1
Manufacture not identified + package damaged + signs of decline* 01 1
Total 12 7 2 8
Signs of decline = sticky, broken, dirty, or high abrasionMalaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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stances. Poor disintegration is considered an important,
but neglected problem in the field of drug quality [30].
For one product tested in this study, the presence of the
stated active ingredient could not be confirmed. These
tablets have been obtained in a shop in Nouna town; they
came from a plastic bag without label and were sold as
sulphadoxine/phyrimethamine. As the letters METRO
were engraved into the tablets, these tablets were most
likely metronidazol (Figure 3). This case exemplifies the
problem of unqualified drug selling practices in the illicit
market, as it has been reported also from neighbouring
countries, too [23].
Although most substandard anti-malarials detected in this
study were found in the illicit market, some were also
found in the licensed market. The majority of these were
quinine tablets. Currently we cannot fully exclude that
these results might be linked to a methodological failure,
as other quinine samples of the same brand were found to
be of good quality. However, as results were confirmed in
the reference laboratory, it was concluded, that some of
the quinine tablets were of substandard concentrations of
the active ingredient. As a consequence, a larger sample
should be tested in the near future for validation. The fact
that different samples of the same product passed or failed
can probably be explained by the use of uncontrolled,
substandard active ingredients during manufacture or
poor manufacturing processes. Nevertheless, to distin-
guish if this was performed deliberately or unintention-
ally will be difficult [32]. It has also been reported that
sometimes poor and good quality tablets are mixed in
same batch, and even tablets in blister packs have been
found to be of mixed standards [8].
The sampling of this study was based on a large and rep-
resentative household survey in the frame of a malaria
control intervention study which was conducted in the
whole NHD in early 2006. The results can thus be consid-
ered as representative for this area of rural West Africa. All
drug quality testing in the field was conducted through
one experienced laboratory scientist (SD) supervised by
the main investigator (MT), and the confirmation tests
were done in a reference laboratory of Germany. Thus, the
validity of this study can be considered as high. As artem-
isinin drugs and ACT were not available at the time of the
study in the NHD apart from private pharmacies in
Nouna town, a convenience sample of these important
drugs was collected in Ouagadougou, the major town of
Burkina Faso. However, as the overall number of drug
samples by drug class tested was rather small, results have
to be interpreted with caution.
It is reassuring, that of the artemisinin and ACT drugs col-
lected and tested only one has been found to be substand-
ard. This product was most likely diverted from the
Drugs sold at an illicit market of Burkina Faso Figure 2
Drugs sold at an illicit market of Burkina Faso.Malaria Journal 2008, 7:95 http://www.malariajournal.com/content/7/1/95
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licensed market to the illicit market, a procedure fre-
quently observed in malaria endemic countries [8]. How-
ever, it is likely that the increasing demand for artemisinin
and ACT drugs will be accompanied by increasing produc-
tion and distribution of substandard and fake products in
the near future [38]. There is already evidence for such a
development from a study conducted in East and Central
Africa on the quality of artemisinin and ACT drugs availa-
ble at private pharmacies [39]. Reports from Tanzania and
Cameroon also indicated the presence of counterfeit dihy-
droartemisinin and counterfeit artesunate in the African
market [38]. As a consequence, appropriate anti-malarial
drug surveillance needs to become established in all coun-
tries of SSA. In addition, governmental drug control
authorities need to be strengthened, access to affordable,
quality controlled drugs needs to be improved, and the
population should become better informed on the risks
associated with buying drugs at the illicit market.
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